These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8562857)

  • 1. Gn-RH agonists in the treatment of prostatic carcinoma.
    Vacher P
    Biomed Pharmacother; 1995; 49(7-8):325-31. PubMed ID: 8562857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New treatment approaches for prostate cancer based on peptide analogues.
    Stangelberger A; Schally AV; Djavan B
    Eur Urol; 2008 May; 53(5):890-900. PubMed ID: 18201818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hormonal therapy in metastatic prostatic cancer].
    Ruffion A; Fontaine E; Staerman F
    Prog Urol; 2003 Apr; 13(2):334-41. PubMed ID: 12765081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
    J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the medical management of prostate cancer.
    Kirby RS
    Br J Clin Pract; 1996 Mar; 50(2):88-93. PubMed ID: 8731645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approaches to the therapy of various tumors based on peptide analogues.
    Schally AV
    Horm Metab Res; 2008 May; 40(5):315-22. PubMed ID: 18491250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Possibilities in drug therapy in prostatic carcinoma].
    Schmid HP
    Ther Umsch; 1995 Jun; 52(6):418-22. PubMed ID: 7541571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.
    Labrie F; Bélanger A; Luu-The V; Labrie C; Simard J; Cusan L; Gomez J; Candas B
    Endocr Rev; 2005 May; 26(3):361-79. PubMed ID: 15867098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG; Crawford ED; DeAntoni EP
    Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine approaches in the therapy of prostate carcinoma.
    d'Ancona FC; Debruyne FM
    Hum Reprod Update; 2005; 11(3):309-17. PubMed ID: 15790600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Will GnRH antagonists improve prostate cancer treatment?
    Huhtaniemi I; White R; McArdle CA; Persson BE
    Trends Endocrinol Metab; 2009 Jan; 20(1):43-50. PubMed ID: 19008119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H; Kanetake H
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gn-RH antagonist possible response, after Gn-RH agonist failure in a man with metastatic prostate cancer.
    Rocco B; Ferrari M; Scardino E; Matei DV; Verweij F; Varela R; De Cobelli O
    Anticancer Res; 2005; 25(1B):577-8. PubMed ID: 15816630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controversies in the management of advanced prostate cancer.
    Tyrrell CJ
    Br J Cancer; 1999 Jan; 79(1):146-55. PubMed ID: 10408706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Usefulness and positioning of MAB therapy for prostate cancer].
    Akaza H; Chodak GW; Hirao Y
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatment of advanced prostate cancer.
    Ismail M; Gomella LG
    Tech Urol; 1997; 3(1):16-24. PubMed ID: 9170220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.